Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK ‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Le résumé fourni par la source

ABSTRACT Clinical development of crizotinib in children with ALK‐positive anaplastic large cell lymphoma (ALCL) was advanced in the US but not in Japan. The objectives of phase 1 part of a clinical study in Japan were to assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of crizotinib in children with relapsed/refractory (R/R) ALK‐positive ALCL or neuroblastoma (NB). Two dose levels (165 and 280 mg/m 2 twice daily (BID)) were planned to be evaluated. The aim of phase 2 part of the study was to assess the antitumor activity of crizotinib at the RP2D in children with R/R ALK‐positive ALCL. Seven patients were eligible for phase 1 part, 5 with ALCL and 2 with NB. All 7 patients received crizotinib at a starting dose of 165 mg/m 2 BID, with 1 dose‐limiting toxicity observed (grade 3 gamma‐glutamyltransferase increased). The most common grade 3 or 4 adverse event was neutropenia (71%). The steady‐state C max and AUC tau of crizotinib at 165 mg/m 2 BID were higher than expected. Considering the risk of a greater incidence of severe neutropenia, we decided that the 165 mg/m 2 BID be the RP2D without evaluation at 280 mg/m 2 BID. A total of 11 patients with ALK‐positive ALCL were enrolled in the phase 2 part. The objective response rate was 72.7% (90% CI, 43.6%–92.1%). One patient permanently discontinued crizotinib due to disease progression. Crizotinib at 165 mg/m 2 BID was well tolerated and showed favorable antitumor activity in children with R/R ALK‐positive ALCL. Trial Registration: UMIN‐CTR: UMIN000028075

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.